Medscape
TOPLINE: Patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) appear to have a very low incidence of nonarteritic anterior ischemic optic neuropathy (NAION) when appropriately prescribed for obesity or diabetes. METHODOLOGY: A retrospective observational study recently suggested that semaglutide treatment may be associated with more than a fourfold increase in the risk for …
Read More
Meta-analysis Probes Rare Potential Vision Risk of GLP-1s
Raleigh Drews
03:22
TOPLINE: Patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) appear to have a very low incidence of nonarteritic anterior ischemic optic neuropathy (NAION) when appropriately prescribed for obesity or diabetes. METHODOLOGY: A retrospective observational study recently suggested that semaglutide treatment may be associated with more than a fourfold increase in the risk for
